메뉴 건너뛰기




Volumn 35, Issue 2, 2010, Pages 108-115

Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model

Author keywords

Bevacizumab; Intraocular; Mouse corneal vascularization; Subconjunctival

Indexed keywords

BEVACIZUMAB; POTASSIUM NITRATE; SILVER NITRATE; VASCULOTROPIN;

EID: 76749160293     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713680903429007     Document Type: Article
Times cited : (37)

References (53)
  • 1
    • 33746621996 scopus 로고    scopus 로고
    • Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision
    • Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA 2006;103:11405-11410.
    • (2006) Proc Natl Acad Sci USA , vol.103 , pp. 11405-11410
    • Cursiefen, C.1    Chen, L.2    Saint-Geniez, M.3
  • 2
    • 33750430869 scopus 로고    scopus 로고
    • Corneal avascularity is due to soluble VEGF receptor-1
    • Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006;443:993-997.
    • (2006) Nature , vol.443 , pp. 993-997
    • Ambati, B.K.1    Nozaki, M.2    Singh, N.3
  • 3
    • 33750551972 scopus 로고    scopus 로고
    • Absence of blood and lymphatic vessels in the developing human cornea
    • Cursiefen C, Rummelt C, Junemann A, et al. Absence of blood and lymphatic vessels in the developing human cornea. Cornea 2006;25:722-726.
    • (2006) Cornea , vol.25 , pp. 722-726
    • Cursiefen, C.1    Rummelt, C.2    Junemann, A.3
  • 4
    • 33947651126 scopus 로고    scopus 로고
    • Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American ophthalmological society thesis)
    • Azar DT. Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American ophthalmological society thesis). Trans Am Opthalmol Soc 2006;104:264-302.
    • (2006) Trans Am Opthalmol Soc , vol.104 , pp. 264-302
    • Azar, D.T.1
  • 5
    • 33947513002 scopus 로고    scopus 로고
    • Proangiogenic role of ephrinB1/ EphB1 in basic fibroblast growth factor-induced corneal angiogenesis
    • Kojima T, Chang JH, Azar DT. Proangiogenic role of ephrinB1/ EphB1 in basic fibroblast growth factor-induced corneal angiogenesis. Am J Pathol 2007;170:764-773.
    • (2007) Am J Pathol , vol.170 , pp. 764-773
    • Kojima, T.1    Chang, J.H.2    Azar, D.T.3
  • 6
    • 35649027831 scopus 로고    scopus 로고
    • Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1
    • Seta F, Patil K, Bellner L, et al. Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1. Prostaglandins Other Lipid Mediat 2007;84:116-127.
    • (2007) Prostaglandins Other Lipid Mediat , vol.84 , pp. 116-127
    • Seta, F.1    Patil, K.2    Bellner, L.3
  • 7
    • 0031766152 scopus 로고    scopus 로고
    • Ocular neovascularization: An epidemiologic review
    • Lee P, Wang CC, Admis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998;43:245-269.
    • (1998) Surv Ophthalmol , vol.43 , pp. 245-269
    • Lee, P.1    Wang, C.C.2    Admis, A.P.3
  • 9
    • 33747750921 scopus 로고    scopus 로고
    • Corticosteroids as antiangiogenic agents
    • Oliver A, Ciulla TA. Corticosteroids as antiangiogenic agents. Ophthalmol Clin North Am 2006;19:345-351.
    • (2006) Ophthalmol Clin North Am , vol.19 , pp. 345-351
    • Oliver, A.1    Ciulla, T.A.2
  • 10
    • 34548815246 scopus 로고    scopus 로고
    • Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: Role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis
    • Nakao S, Hata M, Miura M, et al. Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: Role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis. Am J Pathol 2007;171:1058-1065.
    • (2007) Am J Pathol , vol.171 , pp. 1058-1065
    • Nakao, S.1    Hata, M.2    Miura, M.3
  • 12
    • 11144275177 scopus 로고    scopus 로고
    • Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris
    • Ciulla TA, Criswell MH, Snyder WJ, et al. Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris. Br J Ophthalmol 2005;89:113-119.
    • (2005) Br J Ophthalmol , vol.89 , pp. 113-119
    • Ciulla, T.A.1    Criswell, M.H.2    Snyder, W.J.3
  • 13
    • 0033976911 scopus 로고    scopus 로고
    • Photodynamic therapy for cornel neovascularization using topical administrated photosensitizer ATX-S10(Na) in experimental corneal neovascularization
    • Gohto Y, Obana A, Kanai M, et al. Photodynamic therapy for cornel neovascularization using topical administrated photosensitizer ATX-S10(Na) in experimental corneal neovascularization. Ophthalmic Surg Lasers 2000;31:55-60.
    • (2000) Ophthalmic Surg Lasers , vol.31 , pp. 55-60
    • Gohto, Y.1    Obana, A.2    Kanai, M.3
  • 14
    • 0038238254 scopus 로고    scopus 로고
    • Photodynamic therapy with Verteprofin in a rabbit model of corneal neovascularization
    • Holzer MP, Solomon KD, Vroman DT, et al. Photodynamic therapy with Verteprofin in a rabbit model of corneal neovascularization. Invest Ophthalmol Vis Sci 2003;44:2954-2958.
    • (2003) Invest Ophthalmol Vis Sci , vol.44 , pp. 2954-2958
    • Holzer, M.P.1    Solomon, K.D.2    Vroman, D.T.3
  • 15
    • 60749092838 scopus 로고    scopus 로고
    • The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas
    • Oh JY, Kim MK, Shin MS, et al. The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas. Curr Eye Res 2009;34:85-91.
    • (2009) Curr Eye Res , vol.34 , pp. 85-91
    • Oh, J.Y.1    Kim, M.K.2    Shin, M.S.3
  • 16
    • 34247494559 scopus 로고    scopus 로고
    • Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis
    • Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007;48:25-2552.
    • (2007) Invest Ophthalmol Vis Sci , vol.48 , pp. 25-2552
    • Bock, F.1    Onderka, J.2    Dietrich, T.3
  • 17
    • 38349081535 scopus 로고    scopus 로고
    • Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation
    • Bachmann BO, Bock F, Wiegand SJ, et al. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol 2008;126:71-77.
    • (2008) Arch Ophthalmol , vol.126 , pp. 71-77
    • Bachmann, B.O.1    Bock, F.2    Wiegand, S.J.3
  • 18
    • 44649193281 scopus 로고    scopus 로고
    • Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation
    • Hos D, Bock F, Dietrich T, et al. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest Ophthalmol Vis Sci 2008;49:1836-1842.
    • (2008) Invest Ophthalmol Vis Sci , vol.49 , pp. 1836-1842
    • Hos, D.1    Bock, F.2    Dietrich, T.3
  • 19
    • 33645028105 scopus 로고    scopus 로고
    • Contribution of VEGF and PEDF to choroidal angiogenesis: A need for balanced expressions
    • Tong JP, Yao YF. Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions. Clin Biochem 2006;39:267-276.
    • (2006) Clin Biochem , vol.39 , pp. 267-276
    • Tong, J.P.1    Yao, Y.F.2
  • 20
    • 0037699954 scopus 로고    scopus 로고
    • The biology of VEGF and its receptors
    • Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
    • (2003) Nat Med , vol.9 , pp. 669-676
    • Ferrara, N.1    Gerber, H.P.2    Lecouter, J.3
  • 21
    • 0026485002 scopus 로고
    • Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis
    • Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 1992;359:843-845.
    • (1992) Nature , vol.359 , pp. 843-845
    • Shweiki, D.1    Itin, A.2    Soffer, D.3
  • 22
    • 0033856243 scopus 로고    scopus 로고
    • Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas
    • Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Investi Ophthalmol Vis Sci 2000;41:2514-2522.
    • (2000) Investi Ophthalmol Vis Sci , vol.41 , pp. 2514-2522
    • Philipp, W.1    Speicher, L.2    Humpel, C.3
  • 23
    • 0033941677 scopus 로고    scopus 로고
    • Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization
    • Cursiefen C, Rummelt C, Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 2000;19:526-533.
    • (2000) Cornea , vol.19 , pp. 526-533
    • Cursiefen, C.1    Rummelt, C.2    Kuchle, M.3
  • 24
    • 0031965601 scopus 로고    scopus 로고
    • Requirement for vascular endothelial growth factor in wound- and inflammationrelated corneal neovascularization
    • Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammationrelated corneal neovascularization. Invest Ophthal Vis Sci 1998;39:18-22.
    • (1998) Invest Ophthal Vis Sci , vol.39 , pp. 18-22
    • Amano, S.1    Rohan, R.2    Kuroki, M.3
  • 25
    • 47949107165 scopus 로고    scopus 로고
    • Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis
    • Carrasco MA. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea 2008;27:743-745.
    • (2008) Cornea , vol.27 , pp. 743-745
    • Carrasco, M.A.1
  • 26
    • 64049105964 scopus 로고    scopus 로고
    • Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis
    • Chen WL, Lin CT, Lin NT. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 2009;50:1659-1665.
    • (2009) Invest Ophthalmol Vis Sci , vol.50 , pp. 1659-1665
    • Chen, W.L.1    Lin, C.T.2    Lin, N.T.3
  • 27
    • 38549140058 scopus 로고    scopus 로고
    • Subconjunctival bevacizumab injection for corneal neovascularization
    • Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008;27:142-147.
    • (2008) Cornea , vol.27 , pp. 142-147
    • Bahar, I.1    Kaiserman, I.2    McAllum, P.3
  • 28
    • 34748823112 scopus 로고    scopus 로고
    • Bevacizumab for graft rejection
    • Harooni H, Reddy V, Root T, et al. Bevacizumab for graft rejection. Ophthalmology 2007;114:1950.
    • (2007) Ophthalmology , vol.114 , pp. 1950
    • Harooni, H.1    Reddy, V.2    Root, T.3
  • 29
    • 35348978227 scopus 로고    scopus 로고
    • Subconjunctival bevacizumab for vascularized rejected corneal grafts
    • Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg 2007;33:1991-1993.
    • (2007) J Cataract Refract Surg , vol.33 , pp. 1991-1993
    • Awadein, A.1
  • 30
    • 38549107051 scopus 로고    scopus 로고
    • Bevacizumab (Avastin) eye drops inhibit corneal neovascularization
    • Bock F, Konig Y, Kruse F, et al. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008;246:281-284.
    • (2008) Graefes Arch Clin Exp Ophthalmol , vol.246 , pp. 281-284
    • Bock, F.1    Konig, Y.2    Kruse, F.3
  • 31
    • 33748474191 scopus 로고    scopus 로고
    • Evolving European guidance on the medical management of neovascular age related macular degeneration
    • Chkravarthy U, Soubrane G, Bandello F, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol 2006;90:1188-1196.
    • (2006) Br J Ophthalmol , vol.90 , pp. 1188-1196
    • Chkravarthy, U.1    Soubrane, G.2    Bandello, F.3
  • 32
    • 34247519047 scopus 로고    scopus 로고
    • Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)
    • Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007;91:804-807.
    • (2007) Br J Ophthalmol , vol.91 , pp. 804-807
    • Manzano, R.P.1    Peyman, G.A.2    Khan, P.3
  • 33
    • 34548566924 scopus 로고    scopus 로고
    • The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea
    • Barros LF, Belfort R Jr. The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 2007;79:389-394.
    • (2007) An Acad Bras Cienc , vol.79 , pp. 389-394
    • Barros, L.F.1    Belfort Jr., R.2
  • 34
    • 41149128844 scopus 로고    scopus 로고
    • Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs
    • Hurmeric V, Mumcuoglu T, Erdurman C, et al. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 2008;27:357-362.
    • (2008) Cornea , vol.27 , pp. 357-362
    • Hurmeric, V.1    Mumcuoglu, T.2    Erdurman, C.3
  • 35
    • 41149123475 scopus 로고    scopus 로고
    • Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin)
    • Kim TI, Kim SW, Kim S, et al. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 2008;27:349-352.
    • (2008) Cornea , vol.27 , pp. 349-352
    • Kim, T.I.1    Kim, S.W.2    Kim, S.3
  • 36
    • 39149083043 scopus 로고    scopus 로고
    • Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model
    • Papathanassiou M, Theodossiadis PG, Liarakos VS, et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 2008;145:424-431.
    • (2008) Am J Ophthalmol , vol.145 , pp. 424-431
    • Papathanassiou, M.1    Theodossiadis, P.G.2    Liarakos, V.S.3
  • 37
    • 34247494559 scopus 로고    scopus 로고
    • Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis
    • Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007;48:2545-2552
    • (2007) Invest Ophthalmol Vis Sci , vol.48 , pp. 2545-2552
    • Bock, F.1    Onderka, J.2    Dietrich, T.3
  • 38
    • 34548722080 scopus 로고    scopus 로고
    • Subconjunctival bevacizumab for corneal neovascularization
    • Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2007;245:1577-1599.
    • (2007) Graefes Arch Clin Exp Ophthalmol , vol.245 , pp. 1577-1599
    • Erdurmus, M.1    Totan, Y.2
  • 39
    • 34250315760 scopus 로고    scopus 로고
    • Topical bevacizumab therapy for corneal neovascularization
    • DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007; 125:834-836.
    • (2007) Arch Ophthalmol , vol.125 , pp. 834-836
    • Destafeno, J.J.1    Kim, T.2
  • 40
    • 70349748824 scopus 로고    scopus 로고
    • Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy
    • Oh JY, Kim MK, Wee WR. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy. Cornea 2009;28(9):1070-1073.
    • (2009) Cornea , vol.28 , Issue.9 , pp. 1070-1073
    • Oh, J.Y.1    Kim, M.K.2    Wee, W.R.3
  • 41
    • 65249103986 scopus 로고    scopus 로고
    • Topical bevacizumab in the treatment of corneal neovascularization: Results of a prospective, open-label, noncomparative study
    • Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: Results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009; 127:381-389.
    • (2009) Arch Ophthalmol , vol.127 , pp. 381-389
    • Dastjerdi, M.H.1    Al-Arfaj, K.M.2    Nallasamy, N.3
  • 42
    • 0021878871 scopus 로고
    • Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea
    • Mohoney JM, Waterbury LD. Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res 1985;4:531-535.
    • (1985) Curr Eye Res , vol.4 , pp. 531-535
    • Mohoney, J.M.1    Waterbury, L.D.2
  • 43
    • 33744751811 scopus 로고    scopus 로고
    • The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization
    • Dell S, Peters S, Muther P, et al. The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization. Invest Ophthalmol Vis Sci 2006;47:1928-1937.
    • (2006) Invest Ophthalmol Vis Sci , vol.47 , pp. 1928-1937
    • Dell, S.1    Peters, S.2    Muther, P.3
  • 44
    • 33745413422 scopus 로고    scopus 로고
    • Intracameral bevacizumab for iris rubeosis
    • Tuebingen Bevacizumab Study Group
    • Grisanti S, Biester S, Peters S, et al. Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006;142:158-160.
    • (2006) Am J Ophthalmol , vol.142 , pp. 158-160
    • Grisanti, S.1    Biester, S.2    Peters, S.3
  • 45
    • 66249099523 scopus 로고    scopus 로고
    • Simultaneous intravitreal and intracameral injection of bevacizumab (Avastin) in neovascular glaucoma
    • Yuzbasioglu E, Artunay O, Rasier R, et al. Simultaneous intravitreal and intracameral injection of bevacizumab (Avastin) in neovascular glaucoma. J Ocul Pharmacol Ther 2009;25:259-264.
    • (2009) J Ocul Pharmacol Ther , vol.25 , pp. 259-264
    • Yuzbasioglu, E.1    Artunay, O.2    Rasier, R.3
  • 46
    • 34548721616 scopus 로고    scopus 로고
    • Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: Applying clinical trial results to the treatment of everyday patients
    • Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: Applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627-637.
    • (2007) Am J Ophthalmol , vol.144 , pp. 627-637
    • Brown, D.M.1    Regillo, C.D.2
  • 47
    • 38349122535 scopus 로고    scopus 로고
    • Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: A one-year prospective study
    • Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: A one-year prospective study. Am J Ophthalmol 2008;145:249-256.
    • (2008) Am J Ophthalmol , vol.145 , pp. 249-256
    • Bashshur, Z.F.1    Haddad, Z.A.2    Schakal, A.3
  • 48
    • 36248981014 scopus 로고    scopus 로고
    • Early bevacizumab treatment of central retinal vein occlusion
    • DOI 10.1016/j.ajo.2007.07.038, PII S0002939407006940
    • Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007;144:864-871. (Pubitemid 350122344)
    • (2007) American Journal of Ophthalmology , vol.144 , Issue.6 , pp. 864-871
    • Ferrara, D.C.1    Koizumi, H.2    Spaide, R.F.3
  • 49
    • 36749000600 scopus 로고    scopus 로고
    • Role of intravitreal bevacizumab in neovascular glaucoma
    • Gheith ME, Siam GA, de Barros DS, et al. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 2007;23:487-491.
    • (2007) J Ocul Pharmacol Ther , vol.23 , pp. 487-491
    • Gheith, M.E.1    Siam, G.A.2    De Barros, D.S.3
  • 51
    • 67449141559 scopus 로고    scopus 로고
    • Prevention and treatment of corneal neovascularization: Comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats
    • Hashemian MN, Moghimi S, Kiumehr S, et al. Prevention and treatment of corneal neovascularization: Comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Ophthalmic Res 2009;42:90-95.
    • (2009) Ophthalmic Res , vol.42 , pp. 90-95
    • Hashemian, M.N.1    Moghimi, S.2    Kiumehr, S.3
  • 52
    • 40649128599 scopus 로고    scopus 로고
    • Interaction between bevacizumab and murine VEGF-A: A reassessment
    • Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: A reassessment. Invest Ophthalmol Vis Sci 2008;49:522-527.
    • (2008) Invest Ophthalmol Vis Sci , vol.49 , pp. 522-527
    • Yu, L.1    Wu, X.2    Cheng, Z.3
  • 53
    • 33746541953 scopus 로고    scopus 로고
    • VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial cells
    • Zhao B, Ma A, Cai J, et al. VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial cells. Br J Ophthalmol 2006;90:1052-1059.
    • (2006) Br J Ophthalmol , vol.90 , pp. 1052-1059
    • Zhao, B.1    Ma, A.2    Cai, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.